Time Series Modeling in Medication Prescribing -- Scientific Vs. Promotional Influences

Principal Investigator: Randall S. Stafford, MD, PhD
Funding Agency: Agency for Healthcare Research and Quality
Duration: 12/01/01-12/31/04

Recent Article Publications and Submissions


Stafford RS, Ma J, Finkelstein SN, Haver K, Cockburn I. National trends in asthma visits and asthma pharmacotherapy, 1978-2002. J Allergy Clin Immun, 2003; 111: 729-35.

Ma J, Stafford RS. U.S. physician adherence to standards of asthma pharmacotherapy varies by patient and physician characteristics. J Allergy Clin Immunol, 2003; 112: 633-35.

Stafford RS, MacDonald EM, Finkelstein SN. National patterns of medication therapy for depression, 1987 to 2001. Primary Care Companion J Clin Psych, 2002; 3: 232-235.

Stafford RS, Alehegn T, Finkelstein SN, Cockburn IM, Furberg C, Ma J. The impact of clinical trial results on national trends in alpha-blocker prescribing, 1996-2002. JAMA, 2004; 291: 54-62.

Other Indications
Stafford RS, Radley D. Pill splitting: The potential to achieve cost-savings. Am J Manag Care, 2002; 8: 706-712.

Stafford RS, Radley D. The underutilization of cardiac medications of proven benefit, 1990-2002. J Am Coll Cardiol, 2003; 41: 56-61.

Stafford RS, Radley D. Trends in national patterns of antiobesity medication use. Arch Intern Medicine, 2003; 163: 1046-50.

Ma J, Stafford RS, Finkelstein SN, Cockburn IM. The magnitude and composition of drug promotion in the U.S. Clin Thera, 2003; 25: 1503-17.

Hersh AL, Stefanick ML, Stafford RS. National use of post-menopausal hormone therapy: annual trends and response to recent evidence, 1995-2003. JAMA, 2004; 291: 47-53.

Stafford RS, Drieling RL, Hersh AL. National trends in osteoporosis visits and osteoporosis treatment, 1988-2003. In Press: Arch Intern Med, 2004.

Sehgal NL, Hersh AL, Stafford RS. National patterns of peptic ulcer disease treatment. Submitted to J Gen Intern Med, 2004.

Majumdar SR, Almasi EA, Stafford RS. Pharmaceutical Industry Response to Evidence of Harm: Trends in Spending for Hormone Therapy Promotion After the Women's Health Initiative. Submitted to JAMA, 2004.